Immix Biopharma, Inc. Common Stock
IMMX US45258H1068
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.
Annual Performance 1
| 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -3% | -60% | 212% | -64% | 7% |
Annual Insiders Turnover, USD 2
1 annual and historical performance metrics are recalculated on a daily basis;
2 represents the total value of insider transactions (both buying and selling);
Insider Activity
| Person | Price | Shares | Total | Published | Completed |
|---|---|---|---|---|---|
| Rachman Ilya M CEO |
2.02 USD |
2,500 Bought |
5,050 USD |
17/09/2025 | 17/09/2025 |
| Morris Gabriel S CFO |
1.97 USD |
2,600 Bought |
5,122 USD |
16/09/2025 | 16/09/2025 |
| Morris Gabriel S CFO |
2.28 USD |
2,225 Bought |
5,071 USD |
18/06/2025 | 18/06/2025 |
| Rachman Ilya M CEO |
2.30 USD |
2,178 Bought |
4,999 USD |
18/06/2025 | 18/06/2025 |
| Rachman Ilya M CEO |
2.30 USD |
2,178 Bought |
4,999 USD |
18/06/2025 | 18/06/2025 |
| Morris Gabriel S CFO |
2.28 USD |
2,225 Bought |
5,071 USD |
18/06/2025 | 18/06/2025 |
| Hsu Jason O |
2.19 USD |
40,000 Bought |
87,680 USD |
20/12/2024 | 23/12/2024 |
| Hsu Jason O |
2.17 USD |
7,700 Bought |
16,678 USD |
20/12/2024 | 20/12/2024 |
| Hsu Jason O |
2.25 USD |
8,100 Bought |
18,233 USD |
21/08/2024 | 22/08/2024 |
| Hsu Jason O |
2.23 USD |
15,000 Bought |
33,390 USD |
21/08/2024 | 21/08/2024 |